Dr. Andrew Hendifar (@drhendifar) 's Twitter Profile
Dr. Andrew Hendifar

@drhendifar

I am a physician and scientist working to develop new medications for gastrointestinal malignancies -- particularly pancreatic cancer and neuroendocrine tumors.

ID: 1393737926

linkhttp://www.cedars-sinai.edu/Bios---Physician/H-O/Andrew-E-Hendifar-MD.aspx calendar_today01-05-2013 03:57:41

624 Tweet

892 Followers

494 Following

Dan Theodorescu (@dan_theodorescu) 's Twitter Profile Photo

I’m thrilled by the publication of our Nature Cancer paper using #AI analysis of #multiomic datasets to predict outcomes in #pancreaticcancer patients. This work is the unveiling of the #CedarsSinaiCancer #MolecularTwin. #PDAC Cedars-Sinai Academic Medicine Convergent Science Virtual Cancer Center cedars-sinai.org/newsroom/cedar…

I’m thrilled by the publication of our <a href="/NatureCancer/">Nature Cancer</a> paper using #AI analysis of #multiomic datasets to predict outcomes in #pancreaticcancer patients. This work is the unveiling of the #CedarsSinaiCancer #MolecularTwin. #PDAC <a href="/CedarsSinaiMed/">Cedars-Sinai Academic Medicine</a> <a href="/_CSVCC/">Convergent Science Virtual Cancer Center</a> cedars-sinai.org/newsroom/cedar…
Dr. Andrew Hendifar (@drhendifar) 's Twitter Profile Photo

Novel Molecular Twin Tool May Improve Precision Medicine Care in Patients With Pancreatic Cance - goo.gl/alerts/DnGkZj #GoogleAlerts

Jun Gong (@jgong15) 's Twitter Profile Photo

Highlighting seminal work from #KOL speakers at the 5th Annual Cancer at Cedars-Sinai GI Tumor Conf: Nicholas Nissen: Circulating cells/oncosomes in portal/periph blood for monitoring resectable #PDAC pubmed.ncbi.nlm.nih.gov/38360856/ Mar 23, 2024. Register at cedars.cloud-cme.com/course/courseo… OncoAlert

Highlighting seminal work from #KOL speakers at the 5th Annual <a href="/CSCancerCenter/">Cancer at Cedars-Sinai</a> GI Tumor Conf:

<a href="/DrNickNissen/">Nicholas Nissen</a>: Circulating cells/oncosomes in portal/periph blood for monitoring resectable #PDAC
pubmed.ncbi.nlm.nih.gov/38360856/

Mar 23, 2024. Register at cedars.cloud-cme.com/course/courseo…

<a href="/OncoAlert/">OncoAlert</a>
Jun Gong (@jgong15) 's Twitter Profile Photo

Highlighting seminal work from #KOL speakers at the 5th Annual Cancer at Cedars-Sinai GI Tumor Conf: Dr. Oliver Maddocks: #aminoacid restriction as a novel #PDAC therapeutic strategy pubmed.ncbi.nlm.nih.gov/28425994/ Mar 23, 2024. Register at cedars.cloud-cme.com/course/courseo… OncoAlert CME Program at Cedars-Sinai

Highlighting seminal work from #KOL speakers at the 5th Annual <a href="/CSCancerCenter/">Cancer at Cedars-Sinai</a> GI Tumor Conf:

Dr. Oliver Maddocks: #aminoacid restriction as a novel #PDAC therapeutic strategy
pubmed.ncbi.nlm.nih.gov/28425994/

Mar 23, 2024. Register at cedars.cloud-cme.com/course/courseo…

<a href="/OncoAlert/">OncoAlert</a> <a href="/CMECedarsSinai/">CME Program at Cedars-Sinai</a>
Cancer at Cedars-Sinai (@cscancercenter) 's Twitter Profile Photo

#CedarsSinaiCancer is excited to host the upcoming 5th Annual #GI Tumor Conference on 3/23. Register today! This will be led by course directors Dr. Andrew Hendifar, Jun Gong & Arsen Osipov, MD. #CedarsSinai #Gastroenterology #tumor CME Program at Cedars-Sinai Cedars-Sinai Academic Medicine cmecshs.org/gitumor2024

#CedarsSinaiCancer is excited to host the upcoming 5th Annual #GI Tumor Conference on 3/23. Register today! This will be led by course directors <a href="/DrHendifar/">Dr. Andrew Hendifar</a>, <a href="/jgong15/">Jun Gong</a> &amp; <a href="/DrArsenOsipov/">Arsen Osipov, MD</a>. #CedarsSinai #Gastroenterology #tumor <a href="/CMECedarsSinai/">CME Program at Cedars-Sinai</a> <a href="/CedarsSinaiMed/">Cedars-Sinai Academic Medicine</a> cmecshs.org/gitumor2024
Dr Zuri A. Murrell (@drzurimurrell) 's Twitter Profile Photo

Did you know? When caught early, colorectal cancer has a 90% survival rate. Sharing this post from @coloncancercoalition they have great resources available ➡️ coloncancercoalition.org

Did you know? When caught early, colorectal cancer has a 90% survival rate.

Sharing this post from @coloncancercoalition they have great resources available ➡️ coloncancercoalition.org
Dr. Andrew Hendifar (@drhendifar) 's Twitter Profile Photo

High frequency of germline variants in CFTR identified in PDAC patient... sciencedirect.com/science/articl…. interesting finding in pdac patients who had testing for pancreatitis associated germline variants. Arsen Osipov, MD

Richard Dunne, MD (@drr_dunne) 's Twitter Profile Photo

🚨🚨Hot off the press NEJM In a randomized Ph II Ponsegromab, an anti-GDF15 mAB, increased weight gain, overall physical activity and reduced cachexia symptoms in patients with #cachexia and ⬆️ GDF-15 nejm.org/doi/full/10.10…

🚨🚨Hot off the press <a href="/NEJM/">NEJM</a> 

In a randomized Ph II Ponsegromab, an anti-GDF15 mAB, increased weight gain, overall physical activity and reduced cachexia symptoms in patients with #cachexia and ⬆️ GDF-15

nejm.org/doi/full/10.10…
Dr. Andrew Hendifar (@drhendifar) 's Twitter Profile Photo

As this novel approach to improving weight and performance continues to develop, cancer patients will finally get an opportunity to look and feel like their “old selves”. A great moment for cancer care. ESMO - Eur. Oncology NEJM Pfizer Inc.

Dr. Andrew Hendifar (@drhendifar) 's Twitter Profile Photo

Understanding and Treating Pancreatic Cancer Cachexia | Blog | AACR - goo.gl/alerts/gCyikP #GoogleAlerts. Addressing cancer associated weight loss will become a pillar of cancer care in the near future. #PancreaticCancer Cancer at Cedars-Sinai

Dr. Andrew Hendifar (@drhendifar) 's Twitter Profile Photo

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…. Dual checkpoint inhibition with unprecedented outcomes in MSI-High colorectal cancer. A new standard of care.

Dr. Marwan G. Fakih (@mgfakih) 's Twitter Profile Photo

We have compared the performance ctDNA by Natera vs. imaging in curatively resected colorectal cancer on surveillance. Signatera missed 31% of recurrences (+ imaging and negative Signatera). Largest study of comparative strategies. jamanetwork.com/journals/jaman…